Life Sciences

  • May 26, 2026

    Eli Lilly Expands Vaccine Push With Deals Worth Up To $3.8B

    Eli Lilly and Co. said Tuesday it will buy three companies involved in vaccine development — Curevo Inc., LimmaTech Biologics AG, and Vaccine Company Inc. — for a total of up to roughly $3.83 billion.

  • May 22, 2026

    Law360 Reveals Titans Of The Plaintiffs Bar

    This past year, 10 lawyers across the country at plaintiffs' firms big and small helped secure millions of dollars in settlements and verdicts for their clients, going up against powerful defendants like Google, Monsanto and the Trump administration, earning the attorneys recognition as Law360's Titans of the Plaintiffs Bar for 2026.

  • May 22, 2026

    J&J 's 'Pure' Baby Powder Ads Were Pure Lies, Jury Told

    A University of Toronto marketing professor on Friday told a Los Angeles jury considering bellwether claims that Johnson & Johnson's talc products caused deadly ovarian cancer in three women that the company advertised its talc as "pure" and safe even though its leaders fretted for decades that it could pose health risks.

  • May 22, 2026

    Health Workers Say US Solicitor Wrong In NY Vax Case

    The U.S. solicitor general's position that the nation's highest court shouldn't take up a religious bias suit over a New York state COVID-19 vaccine mandate for healthcare workers incorrectly claimed that accommodations were obtainable, the mandate's challengers told the justices Friday.

  • May 22, 2026

    Healthcare Orgs Push DC Court To Block Student Loan Caps

    Professional organizations representing nurses, therapists, public health workers and educators urged a District of Columbia federal court on Thursday to block a rule by the U.S. Department of Education restricting federal student loan eligibility for a host of degree programs, arguing it exceeded the department's authority.

  • May 22, 2026

    Opioid Plaintiffs Want Sanctions Over McKinsey Deletions

    A group of plaintiffs in multidistrict litigation against McKinsey & Co. is urging a California federal court to sanction the company for deleting communications with Purdue Pharma and other opioid-makers, saying the court should enter a default judgment against the consulting firm.

  • May 22, 2026

    Don't Miss It: Cooley, Simpson Thacher Steer Hot Deals

    A lot can happen in the world of mergers and acquisitions and equity fundraising over the course of a couple of weeks, and it's difficult to keep up with all the deals.

  • May 22, 2026

    Consumer Drops TCPA Suit Against Colo. Supplement Co.

    A Colorado dietary supplement company accused of bombarding consumers with unsolicited telemarketing texts has been let off the hook after the woman who sued it voluntarily dropped the case, according to a filing in Colorado federal court.

  • May 22, 2026

    Trump's Melding Of Politics, Antitrust Hard To Roll Back

    Environmental initiatives, diversity programs, anti-misinformation efforts and gender-affirming care have become central targets for President Donald Trump's antitrust enforcers in what observers say is an increasing trend of politically tinged competition enforcement.

  • May 21, 2026

    PBM Swaps Cravath For WilmerHale In Price-Fixing Suit

    Pharmacy benefit manager Prime Therapeutics LLC has replaced counsel Cravath Swaine & Moore LLP with WilmerHale and another firm in an antitrust case in Michigan federal court brought by the state's attorney general.

  • May 21, 2026

    J&J Used Ellipsis To Nix Asbestos In Report To FDA, Jury Told

    Johnson & Johnson used an ellipsis to eliminate a professor's finding of asbestos in its talc in a report submitted to the U.S. Food and Drug Administration, according to a video deposition shown Thursday to a California jury considering bellwether claims over three women's deadly ovarian cancer.

  • May 21, 2026

    9th Circ. Says Judge Overstepped In Fluoride Risk Case

    A Ninth Circuit panel scrapped a ruling that directed the U.S. Environmental Protection Agency to take action to address potentially unsafe levels of drinking water fluoridation, concluding a California federal judge improperly commandeered the case.

  • May 21, 2026

    NFL Teams Valued At $9B In Stake Sales, And Other Rumors

    Two reported NFL stake sales this past week highlight the continued surge in professional sports valuations, fueled in part by the entry of private equity investors.

  • May 21, 2026

    Insurer Can't Nix Counterclaims In $1.8M Judgment Dispute

    A North Carolina federal judge found that a life sciences company's insurer can't avoid counterclaims brought by a former patent holder asserting that the carrier must cover a $1.77 million judgment entered against the company's executives after they were accused of making misrepresentations about taking the company public.

  • May 21, 2026

    UCB Staves Off Seizure Drug Competition After Bench Trial

    UCB Inc. has persuaded a Delaware federal judge to uphold patents covering its seizure medication Nayzilam, a major win given that generic-drug maker Cipla Ltd. already admitted to infringement.

  • May 21, 2026

    9th Circ. Told To Reject J&J Unit's $442M Antitrust Appeal

    Cardiac catheter refurbisher Innovative Health urged the Ninth Circuit to reject the appeal from Johnson & Johnson's Biosense Webster unit seeking to upend its $442 million antitrust judgment, saying the lower court rightly found that Biosense forced hospitals to avoid refurbished catheters in favor of its own.

  • May 21, 2026

    Vape Sellers Say Pa. E-Cig Law Usurps FDA Authority

    Vape companies are looking to stop a Pennsylvania law that would effectively ban most e-cigarettes, claiming in a federal lawsuit that the statute is unconstitutional, would destroy roughly $2 million of their inventory and targets products that federal regulators say helps smokers quit.

  • May 21, 2026

    Legislative Update: Cannabis And Psychedelics Bill Roundup

    Virginia's governor vetoed legislation to establish adult-use marijuana sales, keeping the state in cannabis legal limbo; Illinois lawmakers introduced legislation to rein in hemp products, aligning state policy with an upcoming shift in federal law; and Louisiana lawmakers sent a bill to the governor that would allow terminally ill patients to access medical marijuana in healthcare facilities. Here are the major moves in cannabis and psychedelics legislation from the past week.

  • May 21, 2026

    BigLaw Deals Scandal Puts Boston Back On White Collar Map

    A sweeping insider trading case involving information stolen from BigLaw firms shows a return to bread-and-butter white collar enforcement for Boston federal prosecutors and provides a morale lift in an office that has seen shifting priorities and staff turnover since the signature "Varsity Blues" takedown in 2019, veteran prosecutors told Law360.

  • May 21, 2026

    Immunity Bid Can't Stop Discovery In THC Abuse Registry Suit

    There's little chance that the Idaho state health director can ditch litigation by mothers challenging the automatic placement of women on the child abuse registry for prenatal THC use, a federal judge said after taking a "preliminary peek" at the state's pending motion to dismiss.

  • May 21, 2026

    Amgen Wants To Preserve Right To Seek Double Tax Relief

    Drugmaker Amgen wants to preserve its right to seek a refund for tax years 2010 through 2015 if the IRS "persists" in taking a position inconsistent with the agency's own arguments pertaining to those years in its audit of 2016 to 2018, the company told the U.S. Tax Court.

  • May 21, 2026

    Texas Comptroller Tells 5th Circ. To Toss E-Cig Ban Suit

    The acting comptroller for Texas is asking the Fifth Circuit to overturn an order allowing vape companies and a trade association to pursue a suit challenging a state law banning e-cigarette products that use liquids from China and other "adversaries," saying the comptroller is entitled to sovereign immunity.

  • May 21, 2026

    Fed. Circ. Backs Lupin Win In Generic Kidney Drug Case

    The Federal Circuit on Thursday affirmed a Delaware federal judge's ruling that Indian generic-drug maker Lupin's version of the kidney disease drug Jynarque does not infringe two patents held by Japanese rival Otsuka.

  • May 21, 2026

    AmeriHealth Unit, PBM Sued Over Prescription Claim Fees

    Two Philadelphia pharmacies have filed a proposed class action against AmeriHealth Caritas Health Plan and its in-house pharmacy benefits manager, PerformRx LLC, claiming the companies violate Pennsylvania law by not disclosing "transmission fees" at the time a claim is run through the pharmacies' computers, according to a complaint removed to federal court.

  • May 21, 2026

    Zantac Cases To Proceed During Appeal Of Recusal Denial

    The Philadelphia judge overseeing the city's Zantac cancer mass tort will not halt proceedings while Keller Postman LLC appeals his refusal to recuse himself from the litigation on the basis that his wife works at Blank Rome LLP, which represents a pharmaceutical company in one of the 550 cases.

Expert Analysis

  • Fresenius Ruling May Shift Anti-Kickback Enforcement

    Author Photo

    The Ninth Circuit's recent decision in Fresenius v. Bonta suggests that businesses have a First Amendment right to donate to certain charities, even if those donations are motivated by economic self-interest, potentially calling into question years of Anti-Kickback Statute proceedings against pharmaceutical manufacturers for making similar donations, says Jonah Knobler at Patterson Belknap.

  • Written Consent Ruling May Signal Change For Telemarketing

    Author Photo

    The Fifth Circuit's ruling in Bradford v. Sovereign Pest Control is a takedown of the Federal Communications Commission's prior express written consent regulation, and because Loper Bright empowers courts to disregard agency interpretations, Telephone Consumer Protection Act litigants now have an opportunity to challenge previously settled FCC regulations, orders and interpretations, say attorneys at Manatt.

  • Series

    Law School's Missed Lessons: How To Draft Pleadings

    Author Photo

    Most law school graduates step into their first jobs without ever having drafted a complaint, answer, motion or other type of pleading, but that gap can be closed by understanding the strategy embedded in every filing, writing with clarity and purpose, and seeking feedback at every step, says Eric Yakaitis at Haug Barron.

  • At The Fed. Circ., Means-Plus-Function Is Not Quite Dead

    Author Photo

    Recent Federal Circuit opinions confirm that means-plus-function claims continue to be drafted, issued, litigated and even infringed — but minding the restrictions imposed over the years by courts and statute requires three steps, says Jay Yates at Patterson & Sheridan.

  • E-Discovery Quarterly: Recent Rulings On ESI Control

    Author Photo

    Several recent federal court decisions have perpetuated a split over what constitutes “control” of electronically stored information — with judges divided on whether the standard should turn on a party's legal right or practical ability to obtain the information, say attorneys at Sidley.

  • Opinion

    USPTO Should Let Inventors Valuate Patents In Prosecution

    Author Photo

    By building patent valuation into the application process, rather than waiting until potential litigation years down the line, the U.S. Patent and Trademark Office would streamline the process for inventors protecting and enforcing their patents, says John Powers at Powers IP.

  • 2 Discovery Rulings Break With Heppner On AI Privilege Issue

    Author Photo

    While a New York federal court’s recent ruling in U.S. v. Heppner suggests that some litigants’ communications with AI tools are discoverable, two other recent federal court decisions demonstrate that such interactions generally qualify for work-product protection under the Federal Rules of Civil Procedure, says Joshua Dunn at Brown Rudnick.

  • Series

    Isshin-Ryu Karate Makes Me A Better Lawyer

    Author Photo

    My involvement in martial arts, specifically Isshin-ryu, which has principles rooted in the eight codes of karate, has been one of the most foundational in the development of my personality, and particularly my approach to challenges — including in my practice of law, says Kaitlyn Stone at Barnes & Thornburg.

  • Microplastics On Water Contaminant List Could Spur Claims

    Author Photo

    The U.S. Environmental Protection Agency's proposal to include microplastics in its draft sixth Contaminant Candidate List under the Safe Drinking Water Act could influence consumer fraud claims and enforcement by state attorneys general, as well as claims against manufacturers from entities facing regulatory compliance costs, says Arie Feltman-Frank at Jenner & Block.

  • USPTO's AI Search Pilot May Reshape Patent Filing Strategy

    Author Photo

    The U.S. Patent and Trademark Office's new artificial intelligence search pilot aims to introduce earlier visibility into the prior art landscape, potentially influencing patent filing considerations and shifting the role of counsel to an earlier stage of the prosecution process, say attorneys at Foley & Lardner.

  • Peptide Policy Is Shifting Toward Sanctioned Compounding

    Author Photo

    The policy landscape for peptides is undergoing a significant shift under the Trump administration, moving toward a complex system of verified compounding and complementary enforcement that will likely bring peptides firmly back into the sphere of legitimate consumer products, say attorneys at Sheppard.

  • Keys To Building Defensible Psychedelic Therapy Programs

    Author Photo

    Given the rapidly evolving legal environment for psychedelic therapies and heightened liability and compliance risks facing providers, meticulous documentation, robust risk management protocols, and proactive engagement with professional organizations and insurers are essential strategies, say Kimberly Chew at Husch Blackwell and L. Alison McInnes at Mindful Health Solutions.

  • Opinion

    State Bars Need To Get Specific About AI Confidentiality

    Author Photo

    Lawyers need to put actual client information into artificial intelligence tools to get their full value, but they cannot confidently do so until state bars offer clear, formal authority on which plan tiers of the three most popular generative AI tools are safe to use when sharing specific client details, says attorney Nick Berk.

  • Series

    Alpine Skiing Makes Me A Better Lawyer

    Author Photo

    Skiing has shaped habits I rely on daily as an attorney — focus, resilience and the ability to remain steady when circumstances shift rapidly — and influences the way I approach legal strategy, client counseling and teamwork, says Isaku Begert at Marshall Gerstein.

  • FDA Guidance May Move Goalposts For Form 483 Responses

    Author Photo

    New draft guidance from the U.S. Food and Drug Administration provides formal insight on how drug manufacturers are expected to respond to Form 483s, raising some concerns about the agency's timelines and expectations, say attorneys at Cooley.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Life Sciences archive.